Clinical Performance of GYNECARE PROSIMA* Pelvic Floor Repair System for Symptomatic Pelvic Organ Prolapse
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Jul 14, 2011
Trial Information
Current as of May 13, 2025
Unknown status
Keywords
ClinConnect Summary
The GYNECARE PROSIMA\* system is a new technique and now available in China. It provides a simplified unanchored mesh repair, making surgery much simpler to perform and reduces the risk of the specific complications that may occur when tunneling devices beyond the pelvic cavity.
In clinical practice, many women have symptomatic prolapse, which requires surgical correction. They are relatively young, and therefore care more about the long-term outcomes and quality of life after procedure. The purpose of this multicenter and prospective study is to evaluate the effectiveness and safety of th...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III, suitable for surgical repair. Vaginal hysterectomy and mid-urethral sling procedures for incontinence may be performed concurrently.
- • Age ≥ 18 years.
- • Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee approved informed consent.
- Exclusion Criteria:
- • Additional surgical intervention concurrent to the procedure (e.g. sacrocolpopexy, paravaginal repair, tubal sterilisation).
- • Previous repair of pelvic organ prolapse involving insertion of mesh.
- • Previous hysterectomy within 6 months of scheduled surgery.
- • Experimental drug or experimental medical device within 3 months prior to the planned procedure.
- • Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
- • Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
- • History of chemotherapy or pelvic radiation therapy.
- • Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spinal cord injury or trauma).
- • Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
- • Nursing or pregnant or intends future pregnancy.
- • Chronic cough not well-controlled.
- • BMI≥30.
- • In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, , China
Guangzhou, Guangdong, China
Fuzhou, Fujian, China
Shenzhen, Guangdong, China
Chengdu, Sichuan, China
Foshan, Guangdong, China
Chengdu, Sichuan, China
Wuxi, Jiangsu, China
Fuzhou, Fujian, China
Xiamen, Fujian, China
Guangzhou, Guangdong, China
Harbin, Heilongjiang, China
Wuhan, Hubei, China
Wuhan, Hubei, China
Changsha, Hunan, China
Nanjing, Jiangsu, China
Shenyang, Liaoning, China
Jinan, Shandong, China
Chengdu, Sichuan, China
Chengdu, Sichuan, China
Mianyang, Sichuan, China
Beijing, , China
Beijing, , China
Chongqin, , China
Patients applied
Trial Officials
Lan Zhu
Principal Investigator
Peking Union Medical College Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials